108 related articles for article (PubMed ID: 10619792)
1. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support.
Bhalla KS; Wilczynski SW; Abushamaa AM; Petros WP; McDonald CS; Loftis JS; Chao NJ; Vredenburgh JJ; Folz RJ
Am J Respir Crit Care Med; 2000 Jan; 161(1):17-25. PubMed ID: 10619792
[TBL] [Abstract][Full Text] [Related]
2. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer.
Wilczynski SW; Erasmus JJ; Petros WP; Vredenburgh JJ; Folz RJ
Am J Respir Crit Care Med; 1998 Feb; 157(2):565-73. PubMed ID: 9476874
[TBL] [Abstract][Full Text] [Related]
3. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
Winer EP; Lindley C; Hardee M; Sawyer WT; Brunatti C; Borstelmann NA; Peters W
Psychooncology; 1999; 8(2):167-76. PubMed ID: 10335560
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Cao TM; Negrin RS; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Taylor TL; Rizk NW; Wong RM; Blume KG; Hu WW
Biol Blood Marrow Transplant; 2000; 6(4):387-94. PubMed ID: 10917574
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
[TBL] [Abstract][Full Text] [Related]
7. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.
Brockstein BE; Smiley C; Al-Sadir J; Williams SF
Bone Marrow Transplant; 2000 Apr; 25(8):885-94. PubMed ID: 10808211
[TBL] [Abstract][Full Text] [Related]
8. The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer.
Marks LB; Rosner GL; Prosnitz LR; Ross M; Vredenburgh JJ; Peters WP
Cancer; 1994 Dec; 74(11):2964-71. PubMed ID: 7954260
[TBL] [Abstract][Full Text] [Related]
9. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
10. Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation.
McGaughey DS; Nikcevich DA; Long GD; Vredenburgh JJ; Rizzieri D; Smith CA; Broadwater G; Loftis JS; McDonald C; Morris AK; Folz RF; Chao NF
Biol Blood Marrow Transplant; 2001; 7(5):274-8. PubMed ID: 11400949
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation.
Todd NW; Peters WP; Ost AH; Roggli VL; Piantadosi CA
Am Rev Respir Dis; 1993 May; 147(5):1264-70. PubMed ID: 8484641
[TBL] [Abstract][Full Text] [Related]
12. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
13. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
[TBL] [Abstract][Full Text] [Related]
14. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.
Cagnoni PJ; Nieto Y; Shpall EJ; Bearman SI; Barón AE; Ross M; Matthes S; Dunbar SE; Jones RB
J Clin Oncol; 1998 May; 16(5):1661-8. PubMed ID: 9586876
[TBL] [Abstract][Full Text] [Related]
16. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.
Laughlin MJ; McGaughey DS; Crews JR; Chao NJ; Rizzieri D; Ross M; Gockerman J; Cirrincione C; Berry D; Mills L; Defusco P; LeGrand S; Peters WP; Vredenburgh JJ
J Clin Oncol; 1998 Mar; 16(3):1008-12. PubMed ID: 9508184
[TBL] [Abstract][Full Text] [Related]
17. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N
Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535
[TBL] [Abstract][Full Text] [Related]
19. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone.
Vredenburgh JJ; Coniglio D; Broadwater G; Jones RB; Ross M; Shpall EJ; Hussein A; Rizzieri D; Marks LB; Gilbert C; Affronti ML; Moore S; McDonald C; Petros WP; Peters WP
Biol Blood Marrow Transplant; 2006 Feb; 12(2):195-203. PubMed ID: 16443517
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
